Name: Tumor Microenvironment (en Inglés)
Price: 447.95 PEN
Availability: InStock
Author: Lee, Peter P. ; Marincola, Francesco M.
ISBN: 9783030388645

portada Tumor Microenvironment (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Lee, Peter P. ; Marincola, Francesco M.

Idioma

Inglés

N° páginas

326

Encuadernación

Tapa Blanda

ISBN13

9783030388645

Categorías

Oncología
Inmunología

Tumor Microenvironment (en Inglés)

Lee, Peter P. ; Marincola, Francesco M. (Autor) · Springer · Tapa Blanda

Libro Nuevo

S/ 447,95

S/ 895,89

Ahorras: S/ 447,95

50% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 05 de Junio y el Jueves 20 de Junio.

Lo recibirás en cualquier lugar de Perú entre 2 y 5 días hábiles luego del envío.

Reseña del libro "Tumor Microenvironment (en Inglés)"

This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.